Compare MYFW & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYFW | LAB |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 326.2M |
| IPO Year | 2018 | 2008 |
| Metric | MYFW | LAB |
|---|---|---|
| Price | $31.36 | $0.69 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $27.00 | $1.35 |
| AVG Volume (30 Days) | 37.9K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.02 | ★ 61.54 |
| EPS | ★ 1.20 | 0.26 |
| Revenue | $96,914,000.00 | ★ $101,937,000.00 |
| Revenue This Year | $20.48 | N/A |
| Revenue Next Year | $9.70 | $2.63 |
| P/E Ratio | $26.18 | ★ $2.58 |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $21.96 | $0.63 |
| 52 Week High | $34.36 | $1.72 |
| Indicator | MYFW | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 40.83 |
| Support Level | $30.08 | $0.63 |
| Resistance Level | $32.59 | $1.02 |
| Average True Range (ATR) | 0.65 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 56.95 | 47.15 |
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.